Business
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical
About this update from Johnson & Johnson
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eJ7NkIHzztwPinGRQcbZqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"text","content":"Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference","length":83,"tagName":"p"},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer, at the 2026 European Lung Cancer Conference.","length":611,"tagName":"p"},{"type":"text","content":"POSTER #297P: Novel Intratumoral Radioenhancer (JNJ -1900) with Chemoradiation and Consolidative Immunotherapy for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC): Early Outcomes from the Phase II CONVERGE Study ","length":221,"tagName":"p"},{"type":"text","content":"Benjamin T. Cooper,1 Jeffrey D. Bradley,2 Sushma Patel,3 Michael A. Pritchett,4 Steven J. Feigenberg,2 Kevin C. Ma,5 Isaac Laniado,6 Melina E. Marmarelis,7 Matthew Scarlotta,8 Joshua K. Sabari,9 Yi -Wen Ma,10 Yina Kuang,10 Kiran Devisetty,10 Balaji Laxmanan,10 David M. DiBardino5","length":280,"tagName":"p"},{"type":"text","content":"Study Conclusions","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs) and did not adversely impact patients’ ability to continue planned therapy","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial efficacy responses observed in 7 patients at first disease evaluation f...